Cancer drug prices and the free‐market forces

The authors discuss why market forces have not been effective in setting cancer drug prices to reasonable levels. Generic cancer drugs are priced too low, which results in drug shortages. Patented cancer drugs are priced too high, which may be harming patients with cancer and the health care system.

Saved in:
Bibliographic Details
Published inCancer Vol. 119; no. 22; pp. 3903 - 3905
Main Authors Kantarjian, Hagop, Zwelling, Leonard
Format Journal Article
LanguageEnglish
Published United States 15.11.2013
Subjects
Antineoplastic Agents - economics
Costs and Cost Analysis
Drug Costs - legislation & jurisprudence
Drug Costs - trends
Drug Industry - economics
Economic Competition
Humans
Neoplasms - drug therapy
Neoplasms - economics
United States
United States
Online AccessGet full text

Cover

More Information
Summary:The authors discuss why market forces have not been effective in setting cancer drug prices to reasonable levels. Generic cancer drugs are priced too low, which results in drug shortages. Patented cancer drugs are priced too high, which may be harming patients with cancer and the health care system.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.28330